Xlife Sciences AG - Asset Resilience Ratio

Latest as of June 2025: 0.01%

Xlife Sciences AG (XLS) has an Asset Resilience Ratio of 0.01% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check XLS capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CHF51.55K

≈ $65.17K USD Cash + Short-term Investments

Total Assets

CHF536.26 Million

≈ $677.97 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2024)

This chart shows how Xlife Sciences AG's Asset Resilience Ratio has changed over time. See XLS net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Xlife Sciences AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see XLS market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF51.55K	0.01%
Short-term Investments	CHF0.00	0%
Total Liquid Assets	CHF51.55K	0.01%

Asset Resilience Insights

Limited Liquidity: Xlife Sciences AG maintains only 0.01% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Xlife Sciences AG Industry Peers by Asset Resilience Ratio

Compare Xlife Sciences AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ascendis Pharma AS NASDAQ:ASND	Biotechnology	0.00%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Spyre Therapeutics Inc. NASDAQ:SYRE	Biotechnology	84.34%
3SBio Inc F:83B	Biotechnology	10.64%
Soleno Therapeutics Inc NASDAQ:SLNO	Biotechnology	20.15%
Jiangxi Fushine Pharmaceutical Co Ltd SHE:300497	Biotechnology	0.02%
Novavax Inc NASDAQ:NVAX	Biotechnology	53.87%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Xlife Sciences AG (2019–2024)

The table below shows the annual Asset Resilience Ratio data for Xlife Sciences AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.02%	CHF99.03K ≈ $125.20K	CHF540.37 Million ≈ $683.18 Million	-0.02pp
2023-12-31	0.04%	CHF218.71K ≈ $276.51K	CHF511.99 Million ≈ $647.30 Million	0.00pp
2022-12-31	0.05%	CHF221.04K ≈ $279.45K	CHF490.23 Million ≈ $619.78 Million	-0.36pp
2021-12-31	0.41%	CHF1.96 Million ≈ $2.47 Million	CHF480.06 Million ≈ $606.93 Million	-2.13pp
2020-12-31	2.53%	CHF4.70 Million ≈ $5.95 Million	CHF185.68 Million ≈ $234.75 Million	+0.88pp
2019-12-31	1.65%	CHF2.54 Million ≈ $3.21 Million	CHF154.02 Million ≈ $194.72 Million	--

pp = percentage points

About Xlife Sciences AG

SW:XLS Switzerland Biotechnology

Market Cap

$182.29 Million

CHF144.19 Million CHF

Market Cap Rank

#18528 Global

#185 in Switzerland

Share Price

CHF25.00

Change (1 day)

+2.04%

52-Week Range

CHF16.55 - CHF26.00

All Time High

CHF52.00